Resources

MSAC position statement on PD-L1 IHC testing to determine eligibility for treatment with PD-(L)1 checkpoint inhibitors

This statement outlines MSAC’s views on the place of programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) testing to help decide eligibility for PD-(L)1 checkpoint inhibitors.

Publication type:
Statement
Date of official publication:
Language:
English
Description:

This statement allows applicants to lodge streamlined codependent applications to request subsidy for PD-L1 IHC testing on a case-by-case basis.

If you wish to seek Medicare Benefits Schedule listing of PD-L1 IHC testing to decide eligibility for treatment with PD-(L)1 checkpoint inhibitors, lodge an application form that addresses the:

  • rationale for PD-L1 IHC testing
  • clinical utility and analytical performance considerations in this statement.
Part of a collection:
MSAC guidelines collection
Last updated:
Tags:
  • MSAC support